Published in Lancet on July 20, 1996
Impact of a DRG-based hospital financing system on quality and outcomes of care in Italy. Health Serv Res (1999) 1.03
Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart (2003) 0.95
Medicine in Italy. Lancet (1996) 0.75
Medicine in Italy. Lancet (1996) 0.75
Medicine in Italy. Lancet (1996) 0.75
Medicine in Italy. Lancet (1996) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med (2001) 8.74
A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med (1995) 7.88
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 7.51
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med (2001) 6.22
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med (1998) 6.17
Multiple primary lung cancers. J Thorac Cardiovasc Surg (1975) 4.97
Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging (2005) 4.88
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet (1999) 4.38
The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care (2001) 3.67
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost (2005) 3.47
Progression, remission, regression of chronic renal diseases. Lancet (2001) 3.17
Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet (1978) 3.15
The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 3.11
Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol (2001) 2.93
Modulating the profit motive to meet needs of the less-developed world. Lancet (2001) 2.86
A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int (2006) 2.85
Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA (2000) 2.76
Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol (1995) 2.73
Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med (1993) 2.70
High-frequency T-DNA-mediated gene tagging in plants. Proc Natl Acad Sci U S A (1989) 2.63
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol (2001) 2.56
Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest (1984) 2.56
Strategies for making more organs available for transplantation. N Engl J Med (2000) 2.48
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int (2001) 2.43
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med (1997) 2.41
APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry (2011) 2.31
Smoking habits and recurrence in Crohn's disease. Gastroenterology (1994) 2.30
Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans (2002) 2.23
Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes. Kidney Int (2007) 2.19
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int (2006) 2.18
The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. Nephrol Dial Transplant (1998) 2.16
The EMIP project. European Myocardial Infarction Project. Eur Heart J (2000) 2.15
Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis (1999) 2.15
Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci (1991) 2.12
Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci (1986) 2.07
The teaching and organisation of clinical pharmacology in European medical schools (W.H.O. Working Group on Clinical Pharmacology). Eur J Clin Pharmacol (1990) 2.07
Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg (1995) 2.06
ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int (2006) 2.05
Has clinical pharmacology lost its way? Lancet (1984) 2.02
Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 2.02
Clinical pharmacokinetics of diazepam. Clin Pharmacokinet (1978) 1.99
Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int (1998) 1.99
Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med (1981) 1.97
Primary sarcomas of the mediastinum: results of therapy. J Thorac Cardiovasc Surg (1998) 1.96
Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules. Eur J Clin Pharmacol (1977) 1.94
Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest (1982) 1.90
"Pap" smear and the risk of cervical neoplasia: quantitative estimates from a case-control study. Lancet (1984) 1.87
Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest (1998) 1.87
Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol (1997) 1.85
Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). N Engl J Med (1993) 1.81
Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg (1998) 1.79
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int (2001) 1.77
ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation (1995) 1.75
North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet (1998) 1.75
Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation (1993) 1.74
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ Res (1995) 1.73
Primary bony and cartilaginous sarcomas of chest wall: results of therapy. Ann Thorac Surg (1992) 1.68
Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation (1997) 1.68
Multiple pulmonary resections in the treatment of osteogenic sarcoma. Ann Thorac Surg (1971) 1.67
Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J (2001) 1.66
Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int (1998) 1.66
Cellular schwannoma: a variety of schwannoma sometimes mistaken for a malignant tumor. Am J Surg Pathol (1981) 1.66
Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant (2006) 1.66
Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study. Am Rev Respir Dis (1984) 1.66
The role of surgery in N2 lung cancer. Surg Clin North Am (1987) 1.65
Feasibility of a large prospective study in general practice: an Italian experience. Gruppo di Studio sulla Pressione Arteriosa nell'Anziano. Br Med J (Clin Res Ed) (1987) 1.65
Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol (1998) 1.64
Oestrogens and obesity as risk factors for endometrial cancer in Italy. Int J Epidemiol (1982) 1.64
Pharmacokinetics of N-demethyldiazepam in patients suffering from insomnia and treated with nortriptyline. Br J Clin Pharmacol (1975) 1.63
Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology (1991) 1.62
Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. Am J Gastroenterol (1999) 1.60
Cyclosporin-induced endothelial cell injury. Lab Invest (1986) 1.60
Self-monitoring of blood glucose in non-insulin-treated diabetic patients: a longitudinal evaluation of its impact on metabolic control. Diabet Med (2005) 1.59
Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol (1993) 1.59
Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. Impact of magnetic resonance imaging. J Thorac Cardiovasc Surg (1994) 1.57
Influence of molecular structure on the tolerogenicity of bacterial dextrans. I. The alpha1--6-linked epitope of dextran B512. Immunology (1975) 1.56
Epidemiology of post-infarction risk stratification strategies in a country with a low volume of revascularization procedures. GISSI-Prognosis Investigators. Eur Heart J (1998) 1.56
Tissue plasminogen activator therapy of rabbit nephrotoxic nephritis. Lab Invest (1990) 1.56
Time to abandon microalbuminuria? Kidney Int (2006) 1.56
Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int (1998) 1.55
Risk factors for myocardial infarction in young women. Am J Epidemiol (1987) 1.55
N-desmethyldiazepam and amylobarbitone sodium as hypnotics in anxious patients. Plasma levels, clinical efficacy and residual effects. Psychopharmacologia (1975) 1.54
Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet (1992) 1.54
Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation (1999) 1.54
Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet (1984) 1.53